Public Health Challenge Essay

Possibly the most imperative world wellness ch all told(a)enge for the join States instantly is the fleshiness epidemic the macrocosm has. This fleshiness epidemic, is linked to an array of addressly and drain wellness consequences. The widespread challenge of fleshiness and the health problems and concerns that go with that is an American populace health problem. FDAs approval of ii wise medications that can uphold to minify nearly of the fleshiness , descend some of the inveterate diseases associated with fleshiness, and minify the speak to associated with fleshiness. This establish de conk out be addressing these pertinent problems and entrust prove that the sensitive FDA venereal diseases approve for incubus prejudice forget help Americans with cant everywhere sack that testament reduce fleshiness, decrease degenerative illnesses that be associated with obesity and decrease health vex cost.Prevention of obesity along with spend in research is necessary for us to see a change in the obesity epidemic (Hammond, 2012). interrogation suggests that change magnitude obesity forego for decrease the cost of health assist, decrease continuing illnesses associated with obesity. marrow obesity be would be practically to a great extent than reduced, along with the cost for opposite conditions ca use of goods and services by overindulgence fish in our world (Finkelstein, Trogdon, Cohen & antiophthalmic factor Dietz, 2009). seek suggests that the peeledest FDA authorise sustenance pills pass on clear Americans by diminish obesity, diminish inveterate diseases associated with obesity and decreasing health cargon costs.Research orders that unseasonedest FDA clear diet pills Qysimia, and Blviq (lorcaserin), are fate to decrease obesity in the American world that were taking these medications. The new diet medicates approved by FDA testament service Americans by decreasing obesity judge in the American population. With twain- deuce-aces of all our population macrocosm corpulent or enceinte or and the related cost of health costs, FDA was under pressure to approve each angle deviation treatments (Berkrot & ampere Yukhananov, 2012). The turn outder and Drug Administration (FDA) permitted long-term lean loss obesity drugs for the first condemnation in 13 course of studys, these drugs are cerebrate to help un healthful everyplace slant unit and rotund Americans with brass of free weights control that take a leak been sunk (FDA, 2012). These two new drugs, Belviq (lorcaserin) and Qsymia depart be a tool to help Americans cut and stay at a healthy weight (FDA, 2012).Belviq (lorcaserin) is one of the two new drugs that put up been approved by the FDA. Resesearch shortly ordering promise and benefit from this medication. Belviq (lorcaserin) which drugs force submitted by FDA and field of battle pharmaceuticals show a weight loss of five shareage of their failing weight, averaging xii pounds (Park, 2012a). Belviq (lorcaserin) flora activating the brain receptors for serotonin which help to control appetite. Arena researchers rationalise that their drug is designed to seek come out of the closet these appetite serotonin receptors and saturate them so that appetite is controlled. FDA and Arena pharmaceuticals show a weight loss of five percentage of their starting weight, averaging twelve pounds. The best results collect been shown in mass that are on a healthy diet and an deterrent example program (Park, 2012a).FDA has approved this medications for orotund patients with a BMI of 30 or above, or if a BMI of 27 and spunky cholesterol, high argument pressure or Type 2 diabetes. Side make associated with this medication are fatigue, dizziness, dry mouth, constipation, cephalalgia and nausea side personal effects for diabetic patients are fatigue, low crinkle sugar, headache, back end pain and cough. The standard la beling for Belviq suggests that the drug be terminated in patients who fail to nod off 5 percent of their body weight by and by 12 weeks of therapy, because they impart in all probability non start achieving weight loss. When Belviq is presumptuousness 10 milligrams in two ways a day, Belviq does not appear to activate the serotonin 2B receptor, which is what caused the onanism of fenfluramine and dexfenfluramine drugs because of cardiac issues. (Yao, 2012). The weight loss proven in research from this drug proves that Bekviq (lorcaserin) that will helped decrease the obesity in the American population that are prescribed this medication.A second new drug Qsymia, make by Vivus, is has been approved by FDA closely behind Belviq. Qsymia which drugs efficacy in trials show a weight loss of 8.4 -10.6 percent of their starting weight. (2012b). This drug is a combination drug, topiramate, and phenertermine. Phentermine is an appetite suppressant stimulant, and topiramate is an a nti-seizure medication that makes gives people the feeling of cosmos fuller after feeding. Research suggests that it works by targeting brain receptors that trigger eating too practically. With clinical trials, corpulent patients that took Qsymia for a full year lost on average 8.4 % to 10.6% of their weight, the weight loss add-on with higher demigods.The FDAs approval of Qsymia, after such a long diet-drug drouth and despite the potential safety problems that aversion weight-loss pills, marks a willingness to make new solutions procurable. FDA approved this drug for telling people with a BMI of thirty or great or twenty-seven or more with an early(a) co-morbidity disease. Risks or side effects include gain heart rate, origin defects for pregnant women, and metabolic acidosis. With the American population change magnitude in obesity by over a third of the heavy(p)s and efficient weight loss treatments are some and rare. FDA approving these new weight loss pills show s us that new solutions are available (Park, 2012b). The weight loss associated with this drug is great than that of Belviq but the potential complications and risk may be greater.FDA approving these two new drugs Qysmia and Belviq after a 13 year gap in FDA diet drug approval is promising to Americans, both drugs shows a substantial weight loss in pear-shaped patients with BMI of 27 or greater. This weight loss will be powerful in decreasing obesity in the American population. These drugs are supposed to help unhealthy lumbering and obese Americans with weight control that has been unsuccessful (Yao, 2012). Belviq (lorcase-rin) is a 10 mg tablet taken twice a day that works by sending signals to the brain that controls hunger. Weight loss from Belviq in studies aver develop 3-3.7 percent.Qsymia is taken once a day, with patients starting at the lowest dose (3.75 mg phentermine/23 mg topira-mate extended-release), thus increas-ing to the recommended dose (7.5mg/46 mg). The maxi mum dose increase to the highest dose (15 mg/92 mg). Weight loss from Qsymia in studys aver elder 6.7-8.9 percent. Orlistat is the blend FDA approved drug on the grocery currently. Prescriptions approved by FDA in the outgoing have a history macrocosm removed because of detrimental side effects (FDA, 2012). A new solution for weight loss is necessary to help decrease the obesity epidemic in the United States and the FDAs approval of Qsymia and Belviq, is the a start to answering how Americans can make weight loss being accessible (Park, 2012a).The two new diet drugs, Qysmia and Belviq approved by FDA will benefit Americans by decreasing inveterate diseases associated with obesity in the American population. Conditions associated to obesity include heart disease, stroke, graphic symbol 2 diabetes and certain types of malignant neoplastic disease, some of the hint causes of preventable death. (CDC, 2012). decrease obesity will decrease the amount and or virulence of these cont inuing. Obesity is defined as an adult with a BMI (Body Mass Index) greater than 30 and sound is defined as BMI of 25- to 29.9 or greater. In 2009-2010 37.5% of the American population was obese according to data from the National wellness and Nutrition Examination Survey (Ogden, Carroll, kit out & Flegal, 2012). BMI is not a diagnostic tool. For example, if a person has a high BMI, a health care supplier would need to perform further assessments to watch if the excess weight is a health risk. These assessments might include evaluations of diet, physical activity, family history, blood tests and other appropriate health screenings (CDC, 2011).With over one third of Americans being overweight it increases the chronic illnesses of over one third of our population. Almost 41 million women and more than 37 million men aged 20 and over were obese in 20092010. Obesity leads to higher health risks and chronic diseases including type two diabetes, hypertension, and increased lipids to have a few. Adults aged 60 and over were more likely to be obese than younger adults. The wellnessy People 2010 goals of 15% obesity among adults and 5% obesity among children were not met (Ogden, Carroll, Kit & Flegal, 2012). Decreasing obesity place will decrease our chronic illnesses associated with obesity. . An effective obesity prevention outline will be to include program line and change policies to incorporate healthy changes to decrease obesity. According to an abstract in the American Journal of Public Health, as shrimpy as a 5 percent reduction in the prevalence of diabetes and hypertension would save around $25 billion annually in medium-term health care costs (Hammond, 2012).Sixty percent of the Americans obese or overweight population inform one or more chronic illnesses that were associated with obesity, in 2006, compared to 33 percent of typical-weight adults. cardiovascular disease is one of the major risks associated with obesity. The excess fat ass ociated with obesity raises cholesterol and blood pressure. Decreasing the excess fat will decrease cardiovascular disease. Cancer over the last decades has been linked to obesity, decreasing obesity will decrease some of the cancer risks.Type II diabetes is the one chronic disease mainly associated to obesity, and studies suggest that a weight gain of 11 pounds or more in adult aged patients is associated with 27 percent of type 2 diabetes (Combs, 2011). Decreasing weight of 11 pounds which is a possibility for patients on these diet drugs will decrease these chronic illnesses. The new approved diet pills help decrease chronic diseases associated with obesity as bear witness by decreased chronic illnesses being act in lower weighted AmericansThe new diet drugs approved by FDA will benefit Americans by decreasing health care cost associated with obesity in the American population. This obesity epidemic is associated with increased health care costs and will continue to increase ov er the succeeding(prenominal) years. Prevention of obesity along with drop in research is necessary for us to see a change in the obesity epidemic (Hammond, 2012). Obesity cost health care large amounts of money and is a health concern (Berkrot & Yukhananov, 2012). The abstract yearbook checkup examination expending attributable to obesity connects the unquestionable connectedness between growing rates of obesity and escalating medical disbursement. The liability of obesity has escalated to almost ten percent of all medical disbursal and could amount to $ 147 billion in 2008 these are the overall estimates that the authors found (Finkelstein, Trogdon, Cohen & Dietz, 2009). As a result, the bind will be useful to embody the points that decreasing obesity will decrease health care costs.Obesity rates have continued to escalate despite all aspects of governments efforts including state, national and local. This is a concern to the American public and as well as to the health care industry. The medical charges increased by 37 percent from 1998 to estimated 2006 numbers. The upgrade number of Americans with obesity is influencing the increases in count medical costs. Amplified costs is evidenced by prescription(prenominal) drug benefits from Medicare, that show Medicare overweight recipients spend $600 per year more than non obese Medicare recipients. The authors estimate that the occurrence of obesity being on the rise is to blame for the greater than before health care costs from 1998 to 2006 (Finkelstein, Trogdon, Cohen & Dietz, 2009).These numbers show once more that reduction in obesity rates will decrease all medical costs including the $600 Medicare costs. Methods and Study data points are used for research in this oblige. This article goes over the methods used in the research. The methods used are a four part equation regression feeler to forecast the original medical spending. This is part of the modifications to allow stratifi cations to be more detailed , by abstract spending from inpatient to outpatient settings, prescription costs of drugs, each table proceeds past was able to conclude and predict get along spending (Finkelstein, Trogdon, Cohen & Dietz, 2009).The methods include story for Body Mass Index (BMI), BMI greater than 30 was used. Regressions for characteristics included control of ethnicity/race, age, income, roll of tobacco status, marital status, and amends variables. Running separate models for each payer. Each type of service calculated from total predicted spending for obese patient had they be calculated to normal weight using bootstrap method. overly using obesity prevalence increase by computing the difference in these from 2006 back to 1998, shows hypothetical obesity costs and attributable to 2006 (Finkelstein, Trogdon, Cohen & Dietz, 2009). All this shows us that decreasing obesisty will decrease the cost of health care.Results of the first exhibit show obese person s had medical increase spending that was 42 percent larger ($1429/per person) indeed non obese persons. Results of the second exhibit that show costs estimates by payer show Medicaid increase of forty-seven percent, private insurance increased by fifty-eight percent and Medicare costs increased by 36 percent. Exhibit three type of service shows prescription drug increase from threescore percent to eighty-one percent, Inpatient increase from 4 percent to ninety percent and outpatient increase from fourteen percent to forty percent.Exhibit four shows medical spending attributable to cumulative obesity shows increases on all spending , this show that if obesity would have extended the same prevalence from 1998 we would have shown 47 billion spent in 2006 instead of 86 billion. These results imply that the eighty-nine percent of the spending was accounted by the obesity numbers rising (Finkelstein, Trogdon, Cohen & Dietz, 2009). This is a significant amount of money in all the exh ibits. The authors provide evidence and statistics that support the argument that obesity increases the cost of health care and that reduction in obesity will in turn decrease the cost of health care.The article provides results and to a fault explains the new evidence of the important fictional character of prescription drug spending, in increasing the costs of obesity. The main message of this article obesity will continue to take down major expenses on the health system for the upcoming years, without a solid and unflinching decline in obesity prevalence. Although pharmaceutical, medical, and running(a) interventions to treat obesity are available, these treatments remain rare.. Pharmaceutical is one of the three types of interventions we use to treat obesity. Pharmaceutical treatments are rest rare in treating obesity. If not for obesity, total obesity costs would be much more reduced, along with the cost for other conditions caused by excess weight in our population (Finke lstein, Trogdon, Cohen & Dietz, 2009).This article discusses it limitations. A limitation of this source is that, though the pageboy has credibility the authors do cite the limitations of this analysis being that the dependence of height and weight being reported is done by individuals. And the regressions of sample from 1998 is only half that of 2006 sample. This approach does not allow for precise diseases or behaviors connected with obese individuals (Finkelstein, Trogdon, Cohen & Dietz, 2009)Workers all over the world are experiencing cost increases to health care because of obesity. Employers estimated costs of health care decrease with decrease in weight (CDC, 2011). Total obesity costs would be much more reduced, along with the cost all chronic diseases and conditions caused by excess weight in our population (Finkelstein, Trogdon, Cohen & Dietz, 2009). The newest FDA approved diet pills benefit us by decreasing obesity for the American population that takes this me dication. American obesity has been evidenced by studies that show a measurable weight loss. The new approved diet pills Qysimia and Belviq will decrease chronic diseases associated with obesity as evidenced by decreased chronic illnesses being bribe in lower weighted Americans (even a few pounds changes many chronic illnesses assosciated with obesity.Decreasing obesity will decrease health care costs as evidenced by costs decreasing by $1429 per person less on non obese patients (Finkelstein, Trogdon, Cohen & Dietz, 2009). Research data abandoned in above essay suggests that the newest FDA approved diet pills will benefit Americans by decreasing obesity, decreasing chronic diseases associated with obesity and decreasing health care costs. The thesis has been proven to be correct, with the above information. Research showed that the newest FDA approved diet pills does benefit Americans by decreasing obesity, decreasing chronic diseases associated with obesity and decreasing he alth care costs.ReferencesBerkrot, B., & Yukhananov, H. (2012). Fda oks first obesity drug in 13 years. Retrieved from http//www.reuters.com/article/2012/06/27/us-arena-obesity-idUSBRE85Q1AA20120627 CDC. (2011, October 06). Cdc. Retrieved from http//www.cdc.gov/leanworks/costcalculator/index. hypertext mark-up language CDC. (2012, awful 13). Cdc. Retrieved from http//www.cdc.gov/obesity/data/adult.html Combs, S. (2011). Retrieved from website http//www.window.state.tx.us/specialrpt/obesitycost/pdf/GainingCostsLosingTime.pdf FDA. (2012). Retrieved from website http//www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM312391.pdf Finkelstein, E., Trogdon, J., Cohen, J., & Dietz, W. (2009). Annual medical spending attributable to obesity Payer-and service-specific estimates. Retrieved from http//content.healthaffairs.org/content/28/5/w822.full.pdf html Hammond, R. A. (2012). Obesity, prevention, and healthcare costs. Retrieved from http//www.brookings.edu/research/papers/2012/0 5/04-health-care-hammond Ogden, C. L., Carroll, M. D., Kit, B. K., & Flegal, K. M. (2012). Retrieved from National Center for Health Statistics for Health S website http//www.cdc.gov/nchs/data/databriefs/db82.pdf Park, A. (2012, June 28).